Ramucirumab in the treatment of non-small cell lung cancer

Expert Opinion on Drug Safety

Volumn 16, Issue 5, 2017, Pages 637-644

  Arrieta, Oscar ^a   Zatarain Barrón, Zyanya Lucia ^a   Cardona, Andrés F ^b,c   Carmona, Amir ^a,d   Lopez Mejia, Mariana ^a  

^a Instituto Nacional de Cancerología   (Colombia)

^b Brain Tumor Section   (Colombia)

^c Foundation for Clinical and Translational Research in Cancer (FICMAC)   (Colombia)

^d LIVER RESEARCH UNIT   (Mexico)

Author keywords

adverse effects; angiogenesis; non small cell lung cancer; Ramucirumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; PACLITAXEL; RAMUCIRUMAB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANGIOGENESIS; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GROWTH; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SURVIVAL RATE; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL RATE;

EID: 85018825910     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1313226     Document Type: Review

References (70)

1. Siegel RL, Miller KD, Jemal A., Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
2. Global Burden of Disease Cancer, C., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015:A systematic analysis for the global burden of disease study. JAMA Oncol. 2016.
3. Arrieta, O., et al. [National consensus of diagnosis and treatment of non-small cell lung cancer]. Rev Invest Clin. 2013;65(Suppl 1):S5–84.
4. Globocan. estimated cancer incidence, mortality and prevalence worldwide 2012 (online predictor analysis). 2012 [cited 2016; Available from:http://globocan.iarc.fr/Pages/burden_sel.aspx
5. Arrieta O, Campos-Parra AD, Zuloaga C, et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012;7(8):1228–1234.
6. Arrieta O, Ramírez-Tirado L-A, Báez-Saldaña R, et al. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”. Lung Cancer. 2015;90(2):161–166.
7. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer:an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–857.
8. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
9. Macedo-Perez, E.O., et al. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2014;74(kkl4):681–690.
10. Manegold C, Dingemans A-MC, Gray JE, et al. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017;12(2):194–207.
11. Shepherd FA. Treatment of advanced non-small cell lung cancer. Semin Oncol. 1994;21(4 Suppl 7):7–18.
12. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523–529.
13. Manegold C. Treatment algorithm in 2014 for advanced non-small cell lung cancer:therapy selection by tumour histology and molecular biology. Adv Med Sci. 2014;59(2):308–313.
14. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist. 2008;13 Suppl 1(Suppl 1):28–36.
15. Yadav L, Puri N, Rastogi V, et al. Tumour Angiogenesis and Angiogenic Inhibitors:A Review. J Clin Diagn Res. 2015;9(6):XE01–XE05.
16. Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2:an update on ramucirumab. Expert Opin Biol Ther. 2013;13(8):1187–1196.
17. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10.
18. Das M, Wakelee H. Angiogenesis and lung cancer:ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC. Transl Lung Cancer Res. 2014;3(6):397–399.
19. Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65(3):550–563.
20. Namiki A, Brogi E, Kearney M, et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem. 1995;270(52):31189–31195.
21. Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer. 2011;2(12):1085–1096.
22. Zhao C, Yang H, Shi H, et al. Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases. Carcinogenesis. 2011;32(8):1143–1150.
23. Welti J, Loges S, Dimmeler S, et al. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123(8):3190–3200.
24. Gacche RN, Meshram RJ. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol. 2013;113(2):333–354.
25. De Mello RA, Costa BM, Reis RM, et al. Insights into angiogenesis in non-small cell lung cancer:molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat Anticancer Drug Discov. 2012;7(1):118–131.
26. Semenza GL. Hydroxylation of HIF-1:oxygen sensing at the molecular level. Physiology (Bethesda). 2004;19:176–182.
27. Siveen, K.S., et al. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization:potential and Challenges. Curr Vasc Pharmacol. 2017.
28. Corti F, Simons M. Modulation of VEGF receptor 2 signaling by protein phosphatases. Pharmacol Res. 2017;115:107–123.
29. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106(11):1311–1319.
30. Farhat FS, Tfayli A, Fakhruddin N, et al. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 2012;84(2):149–160.
31. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996;73(7):931–934.
32. Ohta Y, Tanaka Y, Watanabe G, et al. Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an angiogenesis-associated factor. J Exp Clin Cancer Res. 2007;26(3):301–305.
33. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001;19(2):432–441.
34. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res. 1996;2(8):1411–1416.
35. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8(1):72–79.
36. Shibusa T, Shijubo N, Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res. 1998;4(6):1483–1487.
37. Liao M, Wang H, Lin Z, et al. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33(2–3):125–132.
38. Delmotte P, Martin B, Paesmans M, et al. [VEGF and survival of patients with lung cancer:a systematic literature review and meta-analysis]. Rev Mal Respir. 2002;19(5 Pt 1):577–584.
39. Zheng CL, Qiu C, Shen M-X, et al. Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer:an updated meta-analysis. Asian Pac J Cancer Prev. 2015;16(5):1881–1895.
40. Wadhwa R, Taketa T, Sudo K, et al. Ramucirumab:a novel antiangiogenic agent. Future Oncol. 2013;9(6):789–795.
41. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780–787.• This paper first described the pharmacokinetic and pharmacodynamic parameters associated with treatment with ramucirumab in patients with advanced solid malignancies.
42. Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol. 2015;26(6):1230–1237.
43. Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2014;9(10):1532–1539.• This study was assesed the addition of Ramucirumab to the traditional second-line therapy for NSCLC patients, finding a favorable efficacy and safety profile compared to historical controls.
44. Doebele RC, Spigel D, Tehfe M, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015;121(6):883–892.
45. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639.
46. Yoh K, Hosomi Y, Kasahara K, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016;99:186–193.
47. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL):a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673.•• This pivotal study researched the use of Ramucirumab in second-line treatment of NSCLC, the randomised double blind, phase 3 trial found important benefits in efficacy outcomes along with a tolerable safety profile.
48. Pérol M, Ciuleanu T-E, Arrieta O, et al. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer. 2016;93:95–103.
49. Paz-Ares L. Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL:A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl):abstr 8055.
50. Kazuhiko Nakagawa LP-A, Ponce S, Corral J, et al. randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line egfr mut + stage IV NSCLC:phase 1b safety results. J Thorac Oncol. 2017;12(1):S285.
51. Abdel-Rahman O, ElHalawani H. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab:A meta analysis and summary of other VEGF targeted agents. Crit Rev Oncol Hematol. 2016;102:89–100.•• Study evaluated some of the most common cardiovascular adverse events in patients with solid tumors treated with VEGF targeted agents, including Ramucirumab.
52. Agency EM, Cyramza:summary of product characteristics. 2016 [cited 2017; Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002829/human_med_001825.jsp&mid=WC0b01ac058001d124.
53. Lilly E. Cyramza Product Monograph. 2015. 24January 2017; Available from:http://www.lilly.ca/en/pdf/product-monograph/01_cyramza-pm-16jul2015.pdf.
54. Qi, W.X., et al. Incidence and risk of hypertension associated with ramucirumab in cancer patients:A systematic review and meta-analysis. J Cancer Res Ther. 2016;12(2):775–781.• Systematic review concludes that patients treated with Ramucirumab are under higher risk of developing hypertension, and as such must be closely monitored.
55. Cortinovis D, Gregorc V, Migliorino MR, et al. New perspectives in the second-line treatment of non squamous NSCLC patients:results from a large Italian lung cancer working group. Crit Rev Oncol Hematol. 2017;109:35–41.
56. Peters S. Analysis of early survival in patients with advanced non-squamous NSCLC treated with nivolumab vs docetaxel in checkmate 057. J Thorac Oncol. 2017;12(1):Supplement, Page S253.
57. Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology:current status and future directions. Lancet. 2016;388(10043):518–529.
58. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 2010;102(1):8–18.
59. Al Farsi A, Ellis PM. Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC):is there a role in subsequent lines of therapy? J Thorac Dis. 2015;7(3):214–216.
60. Hegde PS, Jubb AM, Chen D, et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2013;19(4):929–937.
61. Aprile G, Bonotto M, Ongaro E, et al. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment:from benchside to clinical use. Drugs. 2013;73(18):2003–2015.
62. Ferrara N. VEGF-A:a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009;20(4):158–163.
63. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251–275.
64. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
65. Ramalingam SS, Shtivelband M, Soo RA, et al. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(5):433–441.
66. Folkman J. Tumor angiogenesis:therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
67. Roviello G, Bachelot T, Hudis CA, et al. The role of bevacizumab in solid tumours:A literature based meta-analysis of randomised trials. Eur J Cancer. 2017;75:245–258.
68. Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer:truth or fiction? J Immunother Cancer. 2016;4:48.
69. Judith M, Immunotherapy:updates on clinical trials and other insights. 2016; Available from:http://www.springermedizin.at/artikel/53792-immunotherapy-updates-on-clinical-trials-and-other-insights.
70. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.